- Home
- PETS vs GNLX Comparison
PETS vs GNLX Comparison
Compare PETS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- GNLX
- Stock Information
- Founded
- PETS 1996
- GNLX 2001
- Country
- PETS United States
- GNLX United States
- Employees
- PETS N/A
- GNLX N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- GNLX Health Care
- Exchange
- PETS Nasdaq
- GNLX Nasdaq
- Market Cap
- PETS 68.6M
- GNLX 109.4M
- IPO Year
- PETS N/A
- GNLX 2023
- Fundamental
- Price
- PETS $3.15
- GNLX $3.08
- Analyst Decision
- PETS Sell
- GNLX Strong Buy
- Analyst Count
- PETS 2
- GNLX 4
- Target Price
- PETS $3.35
- GNLX $17.75
- AVG Volume (30 Days)
- PETS 127.6K
- GNLX 155.2K
- Earning Date
- PETS 08-05-2025
- GNLX 08-13-2025
- Dividend Yield
- PETS N/A
- GNLX N/A
- EPS Growth
- PETS N/A
- GNLX N/A
- EPS
- PETS 0.02
- GNLX N/A
- Revenue
- PETS $247,010,000.00
- GNLX N/A
- Revenue This Year
- PETS N/A
- GNLX N/A
- Revenue Next Year
- PETS N/A
- GNLX N/A
- P/E Ratio
- PETS $182.84
- GNLX N/A
- Revenue Growth
- PETS N/A
- GNLX N/A
- 52 Week Low
- PETS $2.90
- GNLX $1.60
- 52 Week High
- PETS $6.85
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- PETS 35.84
- GNLX 52.03
- Support Level
- PETS $3.32
- GNLX $2.80
- Resistance Level
- PETS $3.49
- GNLX $3.61
- Average True Range (ATR)
- PETS 0.16
- GNLX 0.23
- MACD
- PETS -0.01
- GNLX 0.02
- Stochastic Oscillator
- PETS 10.00
- GNLX 38.37
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.